I'm not sure that's a question that anyone outside of the true know can effectively answer, but my thought process would be that it depends largely on what the "relaxed criteria" actually are. I'm assuming that the company has kept a record of rejected patients who were screened, which would be a logical place to start looking for any patients who fit the bill. That might make it pretty simple, really. The relaxed criteria could be a simple as lowering the number of drug classes they have shown resistance to in the past, in which case it wouldn't be difficult to transition into recruiting from that pool of potential candidates.
Actually, I'm struggling to come up with criteria changes that would present a large issue for the trial sites, but maybe I'm out of my depth here. Definitely would be interested to hear what others think on this one.
News 
Market Data 
Discover 
